No more waiting for a standing meeting. No submission deadlines. Responsive and flexible—only 10 business days or less from submission to institutional biosafety committee (IBC) review.
The fast and dramatic growth in the field of gene therapy is unprecedented, as the US FDA and regulatory agencies of several other countries have begun issuing approvals for licensed…
With IBC-Ready™, Advarra can help reduce confusion and administrative burden by coordinating with the sponsor, site personnel and local IBC(s) to complete local IBC submission forms.
Advarra’s Director of Biosafety Services Daniel Eisenman discusses the basics of research involving genetic engineering and the role played by the IBC in conducting safe and responsible research.
Advarra's integrated research compliance solutions help make your research altogether better.
Advarra's IBC services provide comprehensive review and support capabilities for clinical, non-clinical and pre-clinical research involving genetic engineering.
IRB-Connect allows seamless access for your data from Advarra's Center for IRB Intelligence (CIRBI) Platform to your eTMF.